Sangamo BioSciences Announces Participation In The 4th Annual Cell & Gene Therapy Investor Day Meeting In New York

Mar 15, 2016, 16:03 ET from Sangamo BioSciences, Inc.

RICHMOND, Calif., March 15, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Elizabeth Wolffe, Ph.D., Sangamo's vice president, corporate communications, will present an overview of the Company's ZFP Therapeutic® programs at 11:15am ET on Tuesday, March 22, 2016, at the 4th Annual Cell & Gene Therapy Investor Day. The meeting will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. A live-streaming webcast of all panels and company presentations will also be available at: http://www.arminvestorday.com/webcast and will be published on the event's website approximately a week after the conference. The presentation will be archived on the Sangamo website for two weeks once the replay of the event is available.

Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, the program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for advanced therapies, as well as offer insight into how these products could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.

Attendance at this event is for credentialed investors and members of the media. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit http://www.arminvestorday.com for more information.

About Sangamo
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures® for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform™ (IVPRP) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating Phase 1/2 clinical trials for hemophilia B, the first in vivo genome editing application cleared by the FDA, and MPS I. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Logo - http://photos.prnewswire.com/prnh/20130102/SF35903LOGO

 

SOURCE Sangamo BioSciences, Inc.



RELATED LINKS

http://www.sangamo.com